Venetoclax and Irinotecan in Relapsed/Refractory SCLC
Stopped AbbVie decided to stop trial involving Venetoclax for safety measures needed
Conditions
- Relapsed Small Cell Lung Cancer
- Refractory Small Cell Lung Carcinoma
Interventions
- DRUG: Venetoclax 50 MG
- DRUG: Venetoclax 100 MG
- DRUG: Venetoclax 200 MG
- DRUG: Venetoclax 400
- DRUG: Venetoclax 600
- DRUG: Irinotecan 60 mg/m2
- DRUG: Venetoclax (RP2D)
Sponsor
Virginia Commonwealth University
Collaborators